PLEASANTON, Calif., Oct. 15,
2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, announced today
the launch of two new Chromium products intended to democratize
access to single cell analysis. The new offerings – GEM-X Flex and
GEM-X Universal Multiplex – introduce significant improvements in
performance, workflow and cost effectiveness, enabling more
researchers to pursue single cell analysis for more
applications.
These launches are part of the company's strategy to drive
widespread adoption of single cell analysis by lowering customer
costs in multiple directions: per cell, per sample, per experiment
and per project. With these advances, 10x Genomics is addressing
the growing demand for high-throughput single cell applications and
providing cost-effective offerings to help new researchers getting
started in single cell and existing labs looking to scale up their
research.
"These launches are an integral part of our ongoing push to
democratize single cell analysis and make it more accessible and
more affordable for more researchers than ever before," said
Michael Schnall-Levin, Founding
Scientist and Chief Technology Officer at 10x Genomics. "They add
to a growing list of new single cell products, protocols and
capabilities that make 2024 the most exciting year of Chromium
innovation in the platform's history. We can't wait to see how labs
of all sizes take advantage of the leading performance, scalability
and affordability of our GEM-X portfolio to fuel their
research."
GEM-X Flex: Superior performance and ultra low
cost per cell
GEM-X Flex Gene Expression brings 10x Genomics' highest
performing and most flexible assay – Chromium Flex – to the
company's new GEM-X technology architecture, delivering superior
performance and substantial cost savings and enabling single cell
analysis at mega scale.
Since its initial launch in 2022, Chromium Flex has delivered
class-leading performance across a broad range of sample types and
became the first and only commercial single cell assay compatible
with FFPE samples. Now on the GEM-X architecture, Flex adds the
scalability to run millions of cells for less than $0.01 per cell. The company believes GEM-X Flex
is the most cost effective single cell product available for
high-throughput applications, including mega-scale CRISPR screens,
cell atlassing projects and multi-site translational studies, among
others.
Key Performance Specifications:
- Ultimate flexibility for low cost at any scale:
Researchers can benefit from the highest sequencing efficiency to
reduce total project costs, as well as fix, batch and run samples
on their own schedule without compromising on data quality.
- Built for mega scale: With GEM-X Flex, researchers can
profile up to 2.5 million cells per run and 5 million cells per
kit, for a cost as low as $0.01 per
cell.
- Unlock previously inaccessible sample types: Flex is the
only single cell assay compatible with a wide range of sample
types: fresh, frozen, PFA-fixed tissue, whole blood, and FFPE
samples.
- Improved sample recovery: With new input recommendations
as low as 25,000 cells per sample, GEM-X Flex delivers a four-fold
improvement in sample recovery and enables researchers to explore
limited samples like small tissue biopsies and flow-sorted
cells.
"Chromium Flex has set a new standard in routine sample
preservation for our core facility users, offering a flexible and
reliable way to preserve biological material for future analysis.
We've already sequenced hundreds of samples and likely have a
multitude more biobanked in the freezer, ready for future studies,"
said Niels Vandamme, Head of VIB
Single Cell Core (Ghent University and KU Leuven). "The GEM-X
Flex workflow is truly the best of both worlds. Researchers can now
take advantage of enhanced sample fixation protocols that require
lower cell input while benefiting from GEM-X's improved cell
capture capabilities. This workflow opens up new possibilities for
both small-scale and high-throughput projects."
GEM-X Flex Gene Expression, compatible exclusively with Chromium
iX and X instruments, is now shipping to customers globally.
GEM-X Universal Multiplex: Easy on-chip
multiplexing delivers significantly lower per sample cost
10x Genomics is also introducing new on-chip multiplexing
capabilities for its flagship GEM-X Universal 3' and 5' Gene
Expression assays, enabling researchers to run more cost-effective
single cell studies even at small scale.
With GEM-X Universal Multiplex, researchers can batch and run
four independent samples, up to 5,000 cells per sample, for
approximately $560 per
sample. On-chip multiplexing allows researchers to combine
cells from up to four samples directly on the chip and collect the
partitioned cells in one recovery well, simplifying the workflow
and reducing hands-on time compared to other sample multiplexing
methods. After sequencing, the samples are distinguished through
computational demultiplexing to streamline the process.
Key Performance Specifications:
- Exceptional performance and superior data quality: GEM-X
Universal Multiplex delivers performance consistent with the
company's flagship GEM-X 3' and 5' Gene Expression kits.
- Significantly lower per sample cost: Perform single cell
analysis for approximately $560 per
sample, expanding access to a wider range of labs and research
projects.
- Broad sample compatibility: Analyze diverse species and
sample types incompatible with other multiplexing methods. The
GEM-X Universal 3' and 5' assays are also compatible with upstream
fixation for flexible sample processing and storage.
- Easy multiplexing workflow: 10x Genomics' unique,
on-chip multiplexing workflow eliminates the need for upstream
sample tagging and enables high cell recovery with low cell input
requirements, ideally suited for limited samples including
organoids and stem cells.
"GEM-X Universal Multiplex not only drives large-scale,
high-throughput projects, but also lowers barriers for new users,"
added Vandamme. "Its clean multiplexing strategy enables
affordable entry into the field without the complexity of
additional labeling requirements, making it ideal for pilot
experiments and easier to scale. On-chip multiplexing simplifies
workflows while making single cell sequencing more accessible to
all."
GEM-X Universal 3' Gene Expression Multiplex is compatible with
Chromium Xo and X instruments. GEM-X Universal 5' Gene Expression
Multiplex is exclusively available on Chromium X instruments. All
GEM-X Universal Multiplex assays are now available for pre-order
and are expected to begin shipping later this quarter.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
scale, configuration, costs, capabilities, adoption and pipeline.
These statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-delivers-single-cell-for-a-single-cent-with-new-chromium-launches-302276878.html
SOURCE 10x Genomics, Inc.
